Microbiome Therapeutic Articles & Analysis
2 articles found
Background: Disruption of the microbiome is key to the pathogenesis of recurrent Clostridioides difficile infection (CDI). Place bo-control led trials assessing microbiome therapeutics have demonstrated efficacy in recurrent CDI; hov/ever, long-term safety and efficacy data from rigorously conducted studies of microbiome ...
Biosortia is building the world’s largest library of microbiome-derived compounds for therapeutic and other applications, by leveraging the company’s microbial harvesting platform to sample and mine aquatic microbiomes at unprecedented scales with sustainable and environmentally friendly approaches. ...